144 related articles for article (PubMed ID: 31858531)
1. TRIM24 aggravates the progression of ovarian cancer through negatively regulating FOXM1 level.
Zhou HE; Pan SS; Han H
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10647-10656. PubMed ID: 31858531
[TBL] [Abstract][Full Text] [Related]
2. LncRNA DANCR aggravates the progression of ovarian cancer by downregulating UPF1.
Pei CL; Fei KL; Yuan XY; Gong XJ
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10657-10663. PubMed ID: 31858532
[TBL] [Abstract][Full Text] [Related]
3. LINC01210 accelerates proliferation, invasion and migration in ovarian cancer through epigenetically downregulating KLF4.
Zhang C; Liu J; Zhang Y; Luo C; Zhu T; Zhang R; Yao R
Biomed Pharmacother; 2019 Nov; 119():109431. PubMed ID: 31514068
[TBL] [Abstract][Full Text] [Related]
4. High expression of TRIM24 predicts worse prognosis and promotes proliferation and metastasis of epithelial ovarian cancer.
Zhang L; Chen H; Ding B; Jiang W
J Ovarian Res; 2022 Feb; 15(1):19. PubMed ID: 35105347
[TBL] [Abstract][Full Text] [Related]
5. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
6. MiR-877 suppresses tumor metastasis via regulating FOXM1 in ovarian cancer.
Fang L; Zhang B; Zhu N
J BUON; 2021; 26(1):229-234. PubMed ID: 33721456
[TBL] [Abstract][Full Text] [Related]
7. FOXM1 promotes hepatocellular carcinoma progression by regulating KIF4A expression.
Hu G; Yan Z; Zhang C; Cheng M; Yan Y; Wang Y; Deng L; Lu Q; Luo S
J Exp Clin Cancer Res; 2019 May; 38(1):188. PubMed ID: 31072351
[TBL] [Abstract][Full Text] [Related]
8. MiRNA-96 accelerates the malignant progression of ovarian cancer via targeting FOXO3a.
Yang N; Zhang Q; Bi XJ
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):65-73. PubMed ID: 31957819
[TBL] [Abstract][Full Text] [Related]
9. LncRNA MEG3 negatively modified osteosarcoma development through regulation of miR-361-5p and FoxM1.
Shen B; Zhou N; Hu T; Zhao W; Wu D; Wang S
J Cell Physiol; 2019 Aug; 234(8):13464-13480. PubMed ID: 30624782
[TBL] [Abstract][Full Text] [Related]
10. OTUB1-catalyzed deubiquitination of FOXM1 facilitates tumor progression and predicts a poor prognosis in ovarian cancer.
Wang Y; Zhou X; Xu M; Weng W; Zhang Q; Yang Y; Wei P; Du X
Oncotarget; 2016 Jun; 7(24):36681-36697. PubMed ID: 27167337
[TBL] [Abstract][Full Text] [Related]
11. LINC01308 accelerates the malignant progression of ovarian cancer by binding to miRNA-506.
Zhang YY; Li P; Zhu MZ; Guo Y; Yang J
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3253-3260. PubMed ID: 31081077
[TBL] [Abstract][Full Text] [Related]
12. PKMYT1 aggravates the progression of ovarian cancer by targeting SIRT3.
Xuan ZH; Wang HP; Zhang XN; Chen ZX; Zhang HY; Gu MM
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5259-5266. PubMed ID: 32495859
[TBL] [Abstract][Full Text] [Related]
13. An integrated model of CDCA5 and FOXM1 expression combined with a residual disease that predicts prognosis in ovarian cancer patients.
Zhang Q; Zhang R; Liu M; Wu H; Yang B
Cell Mol Biol (Noisy-le-grand); 2023 Oct; 69(10):143-149. PubMed ID: 37953569
[TBL] [Abstract][Full Text] [Related]
14. LncRNA SNHG12 accelerates the progression of ovarian cancer via absorbing miRNA-129 to upregulate SOX4.
Sun D; Fan XH
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2345-2352. PubMed ID: 30964158
[TBL] [Abstract][Full Text] [Related]
15. LncRNA MIF-AS1 aggravates the progression of ovarian cancer by sponging miRNA-31-5p.
Fan Y; Wang L; Han XC; Ma HY; Zhang N; Zhe L
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(5):2248-2255. PubMed ID: 32196575
[TBL] [Abstract][Full Text] [Related]
16. The novel circCLK3/miR-320a/FoxM1 axis promotes cervical cancer progression.
Hong H; Zhu H; Zhao S; Wang K; Zhang N; Tian Y; Li Y; Wang Y; Lv X; Wei T; Liu Y; Fan S; Liu Y; Li Y; Cai A; Jin S; Qin Q; Li H
Cell Death Dis; 2019 Dec; 10(12):950. PubMed ID: 31831728
[TBL] [Abstract][Full Text] [Related]
17. MiRNA-8073 targets ZnT1 to inhibit malignant progression of ovarian cancer.
Zhang L; Wang YH; Wang L
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(14):6062-6069. PubMed ID: 31364107
[TBL] [Abstract][Full Text] [Related]
18. FoxM1 promotes epithelial-mesenchymal transition of hepatocellular carcinoma by targeting Snai1.
Yu CP; Yu S; Shi L; Wang S; Li ZX; Wang YH; Sun CJ; Liang J
Mol Med Rep; 2017 Oct; 16(4):5181-5188. PubMed ID: 28849004
[TBL] [Abstract][Full Text] [Related]
19. MiR-216b inhibits osteosarcoma cell proliferation, migration, and invasion by targeting Forkhead Box M1.
Wang W; Guo Z; Yu H; Fan L
J Cell Biochem; 2019 Apr; 120(4):5435-5443. PubMed ID: 30302807
[TBL] [Abstract][Full Text] [Related]
20. DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-β/SMAD4 signaling.
Chan DW; Hui WW; Wang JJ; Yung MM; Hui LM; Qin Y; Liang RR; Leung TH; Xu D; Chan KK; Yao KM; Tsang BK; Ngan HY
Oncogene; 2017 Mar; 36(10):1404-1416. PubMed ID: 27593933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
